Recently, combination therapy of anti-cancer drugs produces higher remmission rates than single agents. One of the most clinically benificial anti-cancer drugs used in combination regimens is Cis-platinum. But its is use has been limited clinically due to many side effects including ototoxicity and nephrotoxicity inspite of good anti-tumor activity. So, the authors studied about the hearing threshold differences, nephrotoxicity and hematologic change after combination therapy including Cis-platinum comparing the level before chemotherapy in 45 patients admitted to Dept. of Gynecology of Hanyang University Hospital due to cervical or ovarian carcinoma. Each patients received one of four chemotherapy. (1) Cis- platinum, Adriamycine and Cytoxan(PAC) (2) Cis-platinum and Bleomycin (3) Cis-platinum, Oncovin and Bleomycin(COB) (4) Cis-platinum. The following results was obtained. (1) Mild ototoxicity at 2KHz, 4KHz and 8KHz level was seen in 15 out of 41 patients(36.6%). 26 patients(64.6%) was unaffected. The median age of the affected patients was 50.6yr(range, 32 to 72 yr), whereas that of the unaffected patients was 43.4 yr(range, 18 to 58 yr). (2) There were no significant change in pure tone audiometry, pure tone average SRT and PB score after 1 cycle infusion of Cis-platinum(range, 50 to 100mg/m²). (3) The significant threshold shift was observed at 4KHz and 8KHz in all patients who received a cumulative dosage of 270mg/m² in PAC and at 2KHz in one of 2 patients(50%) and at 4KHz and 8KHz in all patients who received a cumulative dosage of 525mg/m² in Cis-platinum only. (4) The first significant threshold shift was at 8KHz when the dosage was above 300mg/m² in PAC and Cis-platinum only. (5) The majority of patients did not have nephrotoxicity but two patients had a serum creatinine above 2.0mg% and BUN 20mg%. One case was appeared on combination therapy with COB and the other with Cis-platinum only. (6) Leukopenia less than 3,000/mm³ in 10 patients or 45.5% and anemia less 10gm% of Hb in 5 patients or 22.7% was noted but no patients developed thrombocytopenia in Cis-platinum only. Judging from the results of this study above mentioned, the percents of patients with hearing loss associated with Cis-platinum of the combined chemotherapy was 36.6% and the losses were detected at high frequences above 2KHz. These can be reduced by using mannitol diuresis and hydration. It might be used to the patients with sensorineural or conductive hearing loss carefully and needed of the repeated audiometry test. Nephrotoxicity and hematologic change might be evaluated carefully also.